Nov 16 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc. and Adlai Nortye enter into $86.6 million regional licensing agreement for Reolysin
* Oncolytics Biotech Inc - Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of usd $21.2 million
* Oncolytics Biotech - Co is eligible to receive up to additional $65.4 million upon achievement of clinical, regulatory, commercialization milestones
* Oncolytics Biotech Inc - Upon Adlai Nortye's commercialization of reolysin, Oncolytics is eligible to receive double digit royalty payments
* Oncolytics - Adlai to have exclusive development, commercialization rights to Reolysin in China, Hong Kong, Macau, Singapore, South Korea and Taiwan